6.17p 0.0 0.0%
Last Trade - 09/10/18
| Market Cap | ÂŁn/a |
| Enterprise Value | ÂŁn/a |
| Revenue | ÂŁ11.5m |
| Position in Universe | th / 1805 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 14.6 | 14.1 | 19.9 | 12.0 | 18.7 | 11.5 | 22.6 | 45.9 | -4.7% | ||
| +43.8 | ||||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Vernalis Ltd, formerly Vernalis plc, is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. It also has over four prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.
| Last Annual | June 30th, 2018 |
| Last Interim | June 30th, 2018 |
| Incorporated | October 13, 1988 |
| Public Since | July 1, 1992 |
| No. of Shareholders: | n/a |
| No. of Employees: | 192 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | |
| Exchange | London Stock Exchange |
| Shares in Issue | 526,986,000 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 100 Berkshire Place Wharfedale Road, WOKINGHAM, RG41 5RD, United Kingdom |
| Web | |
| Phone | +44 118 9380000 |
| Auditors | PricewaterhouseCoopers LLP |
As of 09/10/18, shares in Vernalis are trading at 6.17p, giving the company a market capitalisation of ÂŁn/a. This share price information is delayed by 15 minutes.
Shares in Vernalis are currently trading at 6.17p and the price has moved by -52.54% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vernalis price has moved by -52.48% over the past year.
Of the analysts with advisory recommendations for Vernalis, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Vernalis is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Vernalis is scheduled to issue upcoming financial results on the following dates:
Vernalis does not currently pay a dividend.
Vernalis does not currently pay a dividend.
Vernalis does not currently pay a dividend.
To buy shares in Vernalis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Vernalis are currently trading at 6.17p, giving the company a market capitalisation of ÂŁn/a.
Here are the trading details for Vernalis:
We were not able to load our ranking data for Vernalis
We were not able to load any forecast data for Vernalis.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vernalis. Over the past six months, the relative strength of its shares against the market has been 46.8%. At the current price of 6.17p, shares in Vernalis are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Vernalis.
Vernalis's management team is headed by:
Here are the top five shareholders of Vernalis based on the size of their shareholding:
